Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Earnings for Sutro Biopharma, Inc. (STRO)
Earnings in 2023 (TTM): $-88,601,000
According to Sutro Biopharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-88,601,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Sutro Biopharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-88,601,000 | $-106,793,000 |
| 2022 | $-116,704,000 | $-119,204,000 |
| 2021 | $-105,538,000 | $-108,675,000 |
| 2020 | $-32,128,000 | $-36,205,000 |
| 2019 | $-55,744,000 | $-55,744,000 |
| 2018 | $-35,317,000 | $-35,317,000 |
| 2017 | $-19,688,000 | $-19,688,000 |
| 2016 | $1.7 M | $1.7 M |